New Basal Insulin Toujeo Solostar: Increased Therapeutic Potential for the Control of Dysglycaemia in Diabetes Mellitus

Abstract

This review examines the new formulation of insulin glargine (recombinant) in the form of injections 300 U/ml (Gla‑300, Toujeo®). Gla‑300 is a next generation basal insulin with a novel formulation of insulin glargin delivering the same amount of insulin, as Gla‑100 (Lantus®), in 1/3 of the volume. Following the subcutaneous injection, the pharmacokinetic and pharmacodynamic profiles of Gla‑300 are more stable and prolonged (beyond 24 hours) compared with Gla‑100, due to a more gradual and extended release of glargine from the subcutaneous depot (Gla‑300 forms a more compact subcutaneous depot with a smaller surface compared to Gla‑100). The clinical efficacy and safety of Gla‑300 in people with type 1 and type 2 diabetes mellitus are discussed with an emphasis on recently released data from the EDITION (phase 3a) clinical trials. Gla‑300 demonstrates comparable glycaemic control and similar safety profile with lower incidence of hypoglycaemia events (first of all, nocturnal hypoglycemia) compared to Gla‑100. Gla‑300 provided a flexible regimen of insulin administration (24 ± 3 h in the morning vs in the evening) and was associated with less body weight gain.

Authors and Affiliations

V. V. Poltorak

Keywords

Related Articles

Efficacy of Metformin and Atorvastatin in Correction of Indices of Carbohydrate and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus

This paper presents the results of metformin and atorvastatin use in patients with type 2 diabetes mellitus (DM). 25 patients with type 2 diabetes mellitus (DM) had been observed. Patients were treated with metformin and...

State of antioxidant, pro-oxidant and endothelial systems in patients with chronic critical lower limb ischemia and high risk of reperfusion-reoxygenation complications

Background. Obliterating atherosclerosis of the peripheral arterial vessels accounts for more than 20 % of cases of cardiovascular pathology, that is more than in 3 % of the total population. Despite the large experience...

Endothelial dysfunction and methods of its treatment in clinical practice: the role of laser Doppler flowmetry (literature review)

In this literature review, the etiology of endothelial dysfunction is described. Endothelial dysfunction is presented in noninfectious diseases of the 21st century and at the same moment is predictor of cardiovascular an...

Evaluation of androgenic status in patients with primary hypothyroidism

Background. Role of androgenic deficiency in men as a factor of disease pathogenesis is beyond doubt. Interaction of thyroid and sexual hormones in men with hypothyroidism remains controversial. The purpose was to evalua...

Download PDF file
  • EP ID EP201671
  • DOI -
  • Views 86
  • Downloads 0

How To Cite

V. V. Poltorak (2016). New Basal Insulin Toujeo Solostar: Increased Therapeutic Potential for the Control of Dysglycaemia in Diabetes Mellitus. Міжнародний ендокринологічний журнал, 4(76), 59-72. https://europub.co.uk./articles/-A-201671